[go: up one dir, main page]

AR078167A1 - Dispersion solida que comprende un agente anti-vih - Google Patents

Dispersion solida que comprende un agente anti-vih

Info

Publication number
AR078167A1
AR078167A1 ARP100103312A ARP100103312A AR078167A1 AR 078167 A1 AR078167 A1 AR 078167A1 AR P100103312 A ARP100103312 A AR P100103312A AR P100103312 A ARP100103312 A AR P100103312A AR 078167 A1 AR078167 A1 AR 078167A1
Authority
AR
Argentina
Prior art keywords
solid dispersion
understanding
hiv agent
solvate
salt
Prior art date
Application number
ARP100103312A
Other languages
English (en)
Inventor
Ellen Verhoeven
Yves Ruysschaert
Yves Gonnissen
Jody Voorspoels
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of AR078167A1 publication Critical patent/AR078167A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Dispersiones solidas que comprenden un compuesto de la formula (1) o una sal, un solvato o un solvato de una sal del mismo, disperso en un excipiente polimérico, inerte, no toxico, farmacéuticamente aceptable. Procedimiento, uso, método de tratamiento. Reivindicacion 10: Un medicamento que comprende una dispersion solida de acuerdo con cualquiera de las reivindicaciones 1 a 6 en combinacion con al menos un ingrediente activo adicional, preferentemente un ingrediente activo antiretroviralmente.
ARP100103312A 2009-09-11 2010-09-10 Dispersion solida que comprende un agente anti-vih AR078167A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09170133.4A EP2295038B1 (en) 2009-09-11 2009-09-11 Solid dispersion comprising an anti-HIV agent

Publications (1)

Publication Number Publication Date
AR078167A1 true AR078167A1 (es) 2011-10-19

Family

ID=41561428

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103312A AR078167A1 (es) 2009-09-11 2010-09-10 Dispersion solida que comprende un agente anti-vih

Country Status (7)

Country Link
US (1) US20130072531A1 (es)
EP (1) EP2295038B1 (es)
CN (1) CN102573803A (es)
AR (1) AR078167A1 (es)
CA (1) CA2773628A1 (es)
TW (1) TW201127826A (es)
WO (1) WO2011029909A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013175505A1 (en) * 2012-05-21 2013-11-28 Hetero Research Foundation Elvitegravir solid dispersion
DK3383397T3 (da) * 2015-12-02 2021-11-08 Merck Sharp & Dohme Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB453061A (en) 1935-03-23 1936-09-04 Charles Howard Twigg Improvements in and relating to gas heated geysers and water heaters
GB0113524D0 (en) * 2001-06-04 2001-07-25 Hoffmann La Roche Pyrazole derivatives
DE102008015033A1 (de) * 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung

Also Published As

Publication number Publication date
CN102573803A (zh) 2012-07-11
EP2295038B1 (en) 2013-05-29
WO2011029909A1 (en) 2011-03-17
US20130072531A1 (en) 2013-03-21
TW201127826A (en) 2011-08-16
CA2773628A1 (en) 2011-03-17
EP2295038A8 (en) 2011-05-04
EP2295038A1 (en) 2011-03-16

Similar Documents

Publication Publication Date Title
MX372534B (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
CL2017002792A1 (es) Derivados de ciclohexano sustituido con amido
NI201700011A (es) 2-(morfolin-4-il)-1,7-naftiridinas.
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
AR099632A1 (es) Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos
NZ735575A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CR20120345A (es) Derivados de 3-hidroxi-5-arilisotiazol novedosos
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
MX351702B (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de accion sistemica, metodos y usos de las mismas.
MX2017007814A (es) Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico.
ECSP109889A (es) Composiciones terapeuticas y usos de las mismas
PH12014500386A1 (en) Combination treatment for hepatitis c
UY33984A (es) Uso de 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas
AR085616A1 (es) Composicion farmaceutica inhalable que comprende glicopirrolato, uso
ECSP088240A (es) Composición de trazodona para administración una vez por día
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
EP4360621A3 (en) Formulations of bendamustine
BR112015019587A2 (pt) combinações compreendendo compostos maba e corticosteroides
ECSP14023048A (es) Agentes terapéuticos para administración subcutánea optimizados
CO2022006066A2 (es) Agente terapéutico y agente profiláctico para trastornos gastrointestinales funcionales y xerostomía
CO6640318A2 (es) Formas de dosificación oral de bendamustina
CO6460763A2 (es) Métodos y formulaciones ectoparasiticidas
AR078167A1 (es) Dispersion solida que comprende un agente anti-vih
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
PE20151888A1 (es) Metodos para el uso de compuestos de fenoxipropilamina para tratar la depresion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal